Business Context and Reporting Period
WORK Medical Technology Group LTD, a foreign private issuer, filed this Form 6-K on November 24, 2025, covering the month of November 2025. The filing discloses the execution of an "at-the-market" equity sales agreement.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a corporate financing arrangement.
Material Changes
On November 20, 2025, the Company entered into a Sales Agreement with AC Sunshine Securities, LLC. This agreement authorizes the Company to offer and sell Class A ordinary shares with an aggregate offering price of up to $200,000,000. The Company is not obligated to sell any shares under this agreement.
Guidance, Outlook, and Risks
- Offering Structure: Shares will be sold through an "at-the-market offering" as defined by Rule 415(a)(4) under the Securities Act of 1933, based on the Company's instructions regarding price, time, and size.
- Compensation: The Company will pay the Sales Agent a commission of 3.5% of the aggregate gross proceeds from each sale and has agreed to reimburse certain specified expenses.
- Registration: The offering is conducted pursuant to a prospectus supplement dated November 21, 2025, filed under Registration Statement No. 333-289943.
- Risks: The filing notes that the summary is qualified by the full text of the Sales Agreement and that the Company is under no obligation to sell shares.
Investor Verification Checklist
- Verify the actual volume and timing of share sales under the new Sales Agreement in future filings.
- Review the full text of the Sales Agreement (Exhibit 10.1) for specific termination rights and price limitations.
- Monitor the impact of the 3.5% commission on net proceeds should the Company elect to sell shares.
- Check subsequent filings for any actual dilution resulting from this $200 million authorization.